Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sinco Pharmaceuticals Holdings Ltd. ( (HK:6833) ) has provided an update.
Sinco Pharmaceuticals reported a sharp 26.1% drop in 2025 revenue to RMB2.08 billion, driven mainly by a significant decline in sales volume of its core human albumin solution product. Despite the revenue contraction, the group maintained a broadly stable gross margin of 10.7%, though gross profit fell by about RMB77.8 million as lower sales flowed through to profitability.
Net profit slipped 16.9% year on year to RMB34.9 million, reflecting weaker top-line performance, higher finance costs and increased impairment on trade receivables. The board still proposed a reduced final dividend of HK0.167 cents per share, signalling a continued, albeit more cautious, capital return to shareholders amid a tougher operating environment for its plasma-based pharmaceutical portfolio.
The most recent analyst rating on (HK:6833) stock is a Sell with a HK$0.16 price target. To see the full list of analyst forecasts on Sinco Pharmaceuticals Holdings Ltd. stock, see the HK:6833 Stock Forecast page.
More about Sinco Pharmaceuticals Holdings Ltd.
Sinco Pharmaceuticals Holdings Ltd. is a Cayman Islands-incorporated pharmaceutical company listed in Hong Kong that focuses on the production and sale of blood products, with human albumin solution as a key revenue driver. The group operates in the mainland China healthcare market, where demand and pricing for plasma-derived therapies are central to its performance and competitive positioning.
Average Trading Volume: 336,088
Technical Sentiment Signal: Sell
Current Market Cap: HK$353.7M
For detailed information about 6833 stock, go to TipRanks’ Stock Analysis page.